Source: Full-Cycle Biopharmaceutical Complex Worth 103 Billion Teenge to Be Built in Kazakhstan - Official Information Source of the Prime minister of the Republic of Kazakhstan

A major biopharmaceutical investment project will be implemented in the Alatau Special Economic Zone as part of the President of the Republic of Kazakhstan’s instructions to increase the share of domestic pharmaceutical production to 50%. The relevant resolution was signed by Prime Minister Bektenov Olzhas.

The document approves a draft Investment Agreement between the Ministry of Healthcare of the Republic of Kazakhstan and Khan Tengri Biopharma LLP for the construction of a modern full-cycle pharmaceutical manufacturing complex in Alatau SEZ.

The facility will be equipped with advanced technologies and is designed to produce 58 types of medicines. A key focus of the project is the establishment of a full production cycle, including the manufacturing of active pharmaceutical ingredients (APIs).

The production portfolio will include 27 international nonproprietary names (INNs), covering treatments for oncological, autoimmune, rare, and inflammatory diseases.

Total investments in the project will exceed KZT 103 billion. The complex is expected to create more than 180 permanent jobs and contribute to the development of local pharmaceutical manufacturing capacity within Alatau SEZ.

The project is strategically important for strengthening Kazakhstan’s pharmaceutical industry, reducing dependence on imports of socially significant medicines, and forming a sustainable production base. Part of the output is planned for export to the markets of the EAEU, CIS, and Middle Eastern countries.